Clinical overview of the seizure risk of dalfampridine

Bibliography

• Henze T, Rieckmann P, Toyka KV. Multiple Sclerosis Therapy Consensus Group of the German Multiple Sclerosis Society. Symptomatic treatment of multiple sclerosis. Multiple Sclerosis Therapy Consensus Group (MSTCG) of the German Multiple Sclerosis Society. Eur Neurol 2006;56(2):78-105
   PubMed Web of Science ®Google Scholar
• Cohen BA. Identification, causation, alleviation, and prevention of complications (ICAP): an approach to symptom and disability management in multiple sclerosis. Neurology 2008;71(24 Suppl 3):S14-20
   PubMed Web of Science ®Google Scholar
• Thompson AJ, Toosy AT, Ciccarelli O. Pharmacological management of symptoms in multiple sclerosis: current approaches and future directions. Lancet Neurol 2010;9(12):1182-99
   PubMed Web of Science ®Google Scholar
• Samkoff LM, Goodman AD. Symptomatic management in multiple sclerosis. Neurol Clin 2011;29(2):449-63
   PubMed Web of Science ®Google Scholar
• Ampyra® [dalfampridine] extended release tablets prescribing information. Acorda Therapeutics, Inc.; Hawthorne, NY: 2010
   Google Scholar
• Salter AR, Cutter GR, Tyry T, Impact of loss of mobility on instrumental activities of daily living and socioeconomic status in patients with MS. Curr Med Res Opin 2010;26(2):493-500
   PubMed Web of Science ®Google Scholar
• Sutliff MH. Contribution of impaired mobility to patient burden in multiple sclerosis. Curr Med Res Opin 2010;26(1):109-19
   PubMed Web of Science ®Google Scholar
• Goodman AD, Brown TR, Cohen JA, Dose comparison trial of sustained-release fampridine in multiple sclerosis. Neurology 2008;71(15):1134-41
   PubMed Web of Science ®Google Scholar
• Goodman AD, Brown TR, Krupp LB, Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial. Lancet 2009;373(9665):732-8
   PubMed Web of Science ®Google Scholar
• Goodman AD, Brown TR, Edwards KR, A phase 3 trial of extended release oral dalfampridine in multiple sclerosis. Ann Neurol 2010;68(4):494-502
   PubMed Web of Science ®Google Scholar
• Hobart JC, Riazi A, Lamping DL, Measuring the impact of MS on walking ability: the 12-Item MS Walking Scale (MSWS-12). Neurology 2003;60(1):31-6
   PubMed Web of Science ®Google Scholar
• Cornblath DR, Bienen EJ, Blight AR. Dalfampridine: a review of its safety in multiple sclerosis clinical trials. Clin Ther 2012;34(5):1056-69
   PubMed Web of Science ®Google Scholar
• Dunn J, Blight A. Dalfampridine: a brief review of its mechanism of action and efficacy as a treatment to improve walking in patients with multiple sclerosis. Curr Med Res Opin 2011;27(7):1415-23
   PubMed Web of Science ®Google Scholar
• Koch M, Uyttenboogaart M, Polman S, De Keyser J. Seizures in multiple sclerosis. Epilepsia 2008;49(6):948-53
   PubMed Web of Science ®Google Scholar
• Kelley BJ, Rodriguez M. Seizures in patients with multiple sclerosis: epidemiology, pathophysiology and management. CNS Drugs 2009;23(10):805-15
   PubMed Web of Science ®Google Scholar
• Stork CM, Hoffman RS. Characterization of 4-aminopyridine in overdose. J Toxicol Clin Toxicol 1994;32(5):583-7
   PubMed Web of Science ®Google Scholar
• Pickett TA, Enns R. Atypical presentation of 4-aminopyridine overdose. Ann Emerg Med 1996;27(3):382-5
   PubMed Web of Science ®Google Scholar
• Goodman AD, Cohen JA, Cross A, Fampridine-SR in multiple sclerosis: a randomized, double-blind, placebo-controlled, dose-ranging study. Mult Scler 2007;13(3):357-68
   PubMed Web of Science ®Google Scholar
• Banerjee P, Hauser W. Incidence and prevalence. In: Engel J, Pedley T, editors. Epilepsy: a comprehensive textbook. Volume 1 2nd edition. Lippincott Williams & Wilkins; Philadelphia, PA: 2008. p. 45-56
   Google Scholar
• Schuele SU, Kellinhaus C, Shook SJ, Incidence of seizures in patients with multiple sclerosis treated with intrathecal baclofen. Neurology 2005;64(6):1086-7
   PubMed Web of Science ®Google Scholar
• Drugs That May Lower Seizure Threshold. 2004. Available from: http://professionals.epilepsy.com/page/table_seniors_drugs.html [Last accessed 16 May 2010]
   Google Scholar
• Boissy AR, Cohen JA. Multiple sclerosis symptom management. Expert Rev Neurother 2007;7(9):1213-22
   PubMedGoogle Scholar
• Crayton HJ, Rossman HS. Managing the symptoms of multiple sclerosis: a multimodal approach. Clin Ther 2006;28(4):445-60
   PubMed Web of Science ®Google Scholar
• Bruckner C, Heinemann U. Effects of standard anticonvulsant drugs on different patterns of epileptiform discharges induced by 4-aminopyridine in combined entorhinal cortex-hippocampal slices. Brain Res 2000;859(1):15-20
   PubMed Web of Science ®Google Scholar
• Mihaly A, Bencsik K, Solymosi T. Naltrexone potentiates 4-aminopyridine seizures in the rat. J Neural Transm Gen Sect 1990;79(1–2):59-67
   PubMed Web of Science ®Google Scholar
• Yang XF, Rothman SM. Focal cooling rapidly terminates experimental neocortical seizures. Ann Neurol 2001;49(6):721-6
   PubMed Web of Science ®Google Scholar
• Vilagi I, Dobo E, Borbely S, Repeated 4-aminopyridine induced seizures diminish the efficacy of glutamatergic transmission in the neocortex. Exp Neurol 2009;219(1):136-45
   PubMed Web of Science ®Google Scholar
• Spyker DA, Lynch C, Shabanowitz J, Sinn JA. Poisoning with 4-aminopyridine: report of three cases. Clin Toxicol 1980;16(4):487-97
   PubMed Web of Science ®Google Scholar
• Johnson NC, Morgan MW. An unusual case of 4-aminopyridine toxicity. J Emerg Med 2006;30(2):175-7
   PubMed Web of Science ®Google Scholar
• Velez L, Shirazi F, Goto C, Opisthotonic posturing with neuromuscular irritability attributable to 4-aminopyridine ingestion by a healthy pediatric patient. Pediatrics 2003;111(1):e82-4
   PubMed Web of Science ®Google Scholar
• Smeets JW, Kunst MW. Severe poisoning by 4-aminopyridine in a body builder [article in Dutch]. Ned Tijdschr Geneeskd 1995;139(51):2667-9
   PubMedGoogle Scholar
• Burton JM, Bell CM, Walker SE, O'Connor PW. 4-aminopyridine toxicity with unintentional overdosage in four patients with multiple sclerosis. Neurology 2008;71(22):1833-4
   PubMed Web of Science ®Google Scholar
• De Cauwer H, De Wolf P, Couvreur F, Mortelmans L. An unusual case of 4-aminopyridine toxicity in a multiple sclerosis patient: epileptic disorder or toxic encephalopathy? Acta Neurol Belg 2009;109(1):40-1
   PubMed Web of Science ®Google Scholar
• Schwam E. Severe accidental overdose of 4-aminopyridine due to a compounding pharmacy error. J Emerg Med 2011;41(1):51-4
   PubMed Web of Science ®Google Scholar
• Badruddin A, Menon RS, Reder AT. 4-Aminopyridine toxicity mimics autoimmune-mediated limbic encephalitis. Neurology 2009;72(12):1100-1
   PubMed Web of Science ®Google Scholar
• Acorda Therapeutics, Inc. Integrated Summary of Safety. Fampridine-SR in Patients With Multiple Sclerosis. NDA 22-250. 2009
   Google Scholar
• Vollmer T, Henney HR III. Pharmacokinetics and tolerability of single escalating doses of fampridine sustained-release tablets in patients with multiple sclerosis: a phase I – II, open-label trial. Clin Ther 2009;31(10):2206-14
   PubMed Web of Science ®Google Scholar
• Eriksson M, Ben-Menachem E, Andersen O. Epileptic seizures, cranial neuralgias and paroxysmal symptoms in remitting and progressive multiple sclerosis. Mult Scler 2002;8(6):495-9
   PubMed Web of Science ®Google Scholar
• Jara M, Henney HR III, Wessel T, Dalfampridine extended-release tablets: one year of post-marketing safety experience in the United States [abstract]. Mult Scler 2011;17(Suppl 10):S216
   Google Scholar
• Ampyra (Dalfampridine) Extended Release Tablets. Risk Evaluation and Mitigation Strategy. 2010; Available from: www.accessdata.fda.gov/drugsatfda_docs/label/2010/022250s000REMS.pdf [ [Last accessed 6 August 2010]
   Google Scholar
• Panitch H, Applebee A. Treatment of walking impairment in multiple sclerosis: an unmet need for a disease-specific disability. Expert Opin Pharmacother 2011;12(10):1511-21
   PubMed Web of Science ®Google Scholar
• Fountain NB, Freeman JM. EEG is an essential clinical tool: pro and con. Epilepsia 2006;47(Suppl 1):23-5
   PubMedGoogle Scholar
• Wirrell EC. Prognostic significance of interictal epileptiform discharges in newly diagnosed seizure disorders. J Clin Neurophysiol 2010;27(4):239-48
   PubMed Web of Science ®Google Scholar